JPRN-jRCT1080224680已完成4 期
A single arm, open-label, multicenter Phase 2 study of regorafenib in participants who have been treated in a previous Bayer-sponsored regorafenib study (monotherapy or combination treatment) that has reached the primary completion endpoint or the main data analysis, or has been stopped prematurely.
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Inclusion Criteria:
- •- Participant must be age-eligible in the feeder study at the time of signing the informed consent.
- •- Participant is currently participating in any Bayer-sponsored regorafenib study and is receiving study treatment.
- •- Participant is currently benefiting from treatment with regorafenib monotherapy and meets criteria to initiate a subsequent cycle of therapy, as determined by the guidelines of the feeder
- •- Any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and not requiring further treatment interruption by the
- •investigator.
排除标准
- •Exclusion Criteria:
- •- Medical reasons not to start the next treatment cycle in the respective feeder
- •- Pregnancy
研究者
相似试验
进行中（未招募）
1 期
Regorafenib rollover study1. metastatic or unresectable renal cell cancer (RCC) 2. metastatic and/or unresectable gastrointestinal stromal tumors (GIST) 3. metastatic colorectal cancer (CRC) 4. hepatocellular carcinoma (HCC)MedDRA version: 20.0 Level: LLT Classification code 10038407 Term: Renal cell cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10062427 Term: Gastrointestinal stromal tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10073071 Term: Hepatocellular carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003650-24-GBBayer AG15
进行中（未招募）
1 期
Regorafenib rollover study1.metastatic or unresectable renal cell cancer (RCC)2.metastatic and/or unresectable gastrointestinal stromal tumors (GIST)3.metastatic colorectal cancer (CRC)4.hepatocellular carcinoma (HCC)MedDRA version: 21.1Level: LLTClassification code 10038407Term: Renal cell cancerSystem Organ Class: 100000004864EUCTR2018-003650-24-ITBAYER AG15
进行中（未招募）
1 期
Regorafenib rollover studyEUCTR2018-003650-24-DEBayer AG15
招募中
2 期
Regorafenib rollover studySolid TumorsJPRN-jRCT2031230602Tanigawa Takahiko1
已完成
2 期
A Phase 2 Multicenter, Open-label, Single-arm Study of KTE-C19 in Japanese Patients with Refractory or Relapsed Large B Cell LymphomaRefractory or relapsed (relapse after transplant or relapse after medication in patients ineligible for transplant) diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), transformed follicular lymphoma (TFL) or High-grade B cell lymphomaJPRN-jRCT1080223858Gilead Sciences K.K.10